ImmunityBio (IBRX) said Wednesday it has entered into a collaboration and supply agreement with BeiGene to conduct a phase 3 clinical trial combining BeiGene's tislelizumab and ImmunityBio's Anktiva as a potential therapy for the advanced or metastatic non-small cell lung cancer in patients who have acquired resistance to immune checkpoint inhibitors therapy.
Financial terms of the collaboration weren't disclosed.
ImmunityBio said it will conduct the confirmatory phase 3 trial across multiple sites and among 462 participants.
The primary endpoint of the study is overall survival, while secondary endpoints include disease control rate, progression-free survival, objective response rate, and safety, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。